USCOM LIMITED — Regulatory Filings 2012

Jul 30, 2012

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

USCOM “State of the Art” for hypertension in pregnancy

Tuesday 31st of July 2012: Uscom (ASX code: UCM).

Uscom Ltd today announced three presentations at the international society for Hypertension in Pregnancy (ISSHP) in Geneva Switzerland. The presentations included a State of the Art lecture and demonstration of the use of USCOM by Professor Valensise of the Department of Obstetrics and Gynaecology at the University of Rome Tor Vergata.

Hypertension is the leading cause of maternal and peri-natal mortality and morbidity globally, and Professor Valensise’s presentation demonstrated how he uses USCOM to improve the management of hypertension in pregnancy in his “state of the art” lecture.

An additional 2 research papers were presented at the ISSHP meeting in Geneva demonstrating the potential contribution USCOM can make to improving maternal and fetal care in this important clinical group. The research was presented by Dr Scala and colleagues from the Department of Obstetrics and Gynaecology of the University of Rome Tor Vergata, and by Dr Goodyear and colleagues from the Department of Fetal Medicine, Institute for Women’s Health, University College London Hospitals, London, UK.

Dr Goodyear’s group concluded from their study “This simple technique (USCOM) is likely to facilitate large scale studies of maternal cardiovascular function in pregnancy.” This research was also presented at the meeting of the International Society for Obstetric Medicine in Oxford, UK in early July 2012.

Executive Chairman of Uscom, Rob Phillips said, “Hypertension in pregnancy is another critical clinical market in which USCOM is now being recognized. These studies confirm that USCOM use will improve the outcomes of mothers and babies, and it’s applications like these for which USCOM was developed. These studies confirm that USCOM is a standard of care platform technology, and suggests the home care hypertension market is a future focus for our Company.”

Healthy pregnancy requires a normal increase in circulation to support the growth of the fetus. The accurate and early identification of circulatory abnormalities allows accurate intervention to improve maternal and fetal outcomes. Due to the noninvasive and accurate nature of USCOM, it is ideal for guiding interventions in the sensitive maternal circulation.

References:

Gemma Goodyear, Ehizele Joseph, Asma Khalil “Cardiac output and systemic vascular resistance in normal pregnancy.” International Society for Obstetric Medicine – Oxford, UK. July 7-8. Herbert Valensise. “Preeclampsia is a heart disease.” – State of the Art lecture. International Society for Study of Hypertension in Pregnancy. Geneva, Switzerland July 2012. Goodyear G, Joseph E, Khalil A. “Cardiac output and systemic vascular resistance in normal pregnancy and in control non-pregnant women.” Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 2012;2(3):292-293

Scala RL, Tiralongo GM, Pisani I, Gagliardi G, Lo Presti D, Valensise H. “Total vascular resistances in early pregnancy: A key to understand maternal factors inducing spontaneous abortion.” Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 2012;2(3),LB007.

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

About Uscom

Uscom Limited is an Australian medical device company which listed on the Australian Stock Exchange in December 2003. Uscom has developed a Non Invasive Cardiac Output Monitor. The USCOM is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency and Intensive Care Medicine and Anesthesia, and is a tool of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.

USCOM has global regulatory approval and the device is currently marketed in North America, South America, Europe, the Middle East, Australia & New Zealand, China and SE Asia.

Uscom Contacts Rob Phillips Executive Chairman rob@uscom.com.au

Tom Rowe Company Secretary secretary@uscom.com.au